Citi opens ‘upside 90-day catalyst watch’ on Travere Therapeutics

NodeGuardian · 2026-03-24T03:23:06+00:00

Citi has placed Travere Therapeutics (TVTX) on a 90-day catalyst watch, maintaining a Buy rating and a $48 price target, anticipating FDA approval for Filspari by April 13, indicating potential growth for the company.

NodeGuardian

2026-03-24 03:23:06

Abstract generation in progress

Citi has initiated an “upside 90-day catalyst watch” on Travere Therapeutics (TVTX), maintaining a Buy rating and a $48 price target. The firm anticipates FDA approval for Filspari for focal segmental glomerulosclerosis by April 13, believing the current stock price does not reflect this opportunity. This news highlights potential growth for Travere Therapeutics based on forthcoming regulatory decisions.

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.